Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.

[1]  T. Patterson,et al.  A Reference Laboratory Experience of Clinically Achievable Voriconazole, Posaconazole, and Itraconazole Concentrations within the Bloodstream and Cerebral Spinal Fluid , 2013, Antimicrobial Agents and Chemotherapy.

[2]  Amanda Blackford,et al.  Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. , 2013, Diagnostic microbiology and infectious disease.

[3]  J. Vehreschild,et al.  Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome – still an open question? , 2010, Leukemia & lymphoma.

[4]  M. Rinaldi,et al.  Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience , 2009, Antimicrobial Agents and Chemotherapy.

[5]  G. Krishna,et al.  Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.

[6]  J. Sivik,et al.  Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up , 2008, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[7]  J. Steele,et al.  Fatal Aspergillus fumigatus and Candida glabrata infections with posaconazole prophylaxis after stem cell transplantation. , 2008, International journal of antimicrobial agents.

[8]  O. Cornely,et al.  Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome , 2008, Pharmacotherapy.

[9]  G. Socié,et al.  Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation , 2008, Bone Marrow Transplantation.

[10]  C. Lass‐Flörl,et al.  Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing , 2008, Antimicrobial Agents and Chemotherapy.

[11]  P. Chandrasekar,et al.  Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft‐versus‐Host Disease , 2007, Pharmacotherapy.

[12]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[13]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[14]  E. Anaissie,et al.  Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant Recipients , 2006, Antimicrobial Agents and Chemotherapy.

[15]  E. Estey,et al.  Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies , 2006, Antimicrobial Agents and Chemotherapy.

[16]  R. Courtney,et al.  Oral Bioavailability of Posaconazole in Fasted Healthy Subjects , 2005, Clinical pharmacokinetics.

[17]  E. Estey,et al.  Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high‐risk myelodysplastic syndrome undergoing induction chemotherapy , 2004, Cancer.

[18]  H. Kantarjian,et al.  Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy , 2004, Cancer.

[19]  E. Radwanski,et al.  Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. , 2003, British journal of clinical pharmacology.

[20]  R. Courtney,et al.  Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults , 2003, Antimicrobial Agents and Chemotherapy.

[21]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.